How do CARs work? Early insights from recent clinical studies targeting CD19 Journal Article
| Authors: | Davila, M. L.; Brentjens, R.; Wang, X. Y.; Riviere, I.; Sadelain, M. |
| Article Title: | How do CARs work? Early insights from recent clinical studies targeting CD19 |
| Abstract: | Second-generation chimeric antigen receptors (CARs) are powerful tools to redirect antigen-specific T cells independently of HLA-restriction. Recent clinical studies evaluating CD19-targeted T cells in patients with B-cell malignancies demonstrate the potency of CAR-engineered T cells. With results from 28 subjects enrolled by five centers conducting studies in patients with chronic lymphocytic leukemia (CLL) or lymphoma, some insights into the parameters that determine T-cell function and clinical outcome of CAR-based approaches are emerging. These parameters involve CAR design, T-cell production methods, conditioning chemotherapy as well as patient selection. Here, we discuss the potential relevance of these findings and in particular the interplay between the adoptive transfer of T cells and pre-transfer patient conditioning. |
| Keywords: | immunotherapy; gene therapy; chimeric antigen receptor; in-vivo; acute lymphoblastic-leukemia; chronic lymphocytic-leukemia; antitumor-activity; bone-marrow; cd28; adoptive; human t-cells; adoptive t-cell therapy; cd19; chimeric antigen receptors; enhanced survival |
| Journal Title: | OncoImmunology |
| Volume: | 1 |
| Issue: | 9 |
| ISSN: | 2162-4011 |
| Publisher: | Landes Bioscience |
| Date Published: | 2012-12-01 |
| Start Page: | 1577 |
| End Page: | 1583 |
| Language: | English |
| DOI: | 10.4161/onci.22524 |
| ACCESSION: | WOS:000316281700013 |
| PROVIDER: | wos |
| PMCID: | PMC3525612 |
| PUBMED: | 23264903 |
| PMCID: | PMC3525612 |
| PUBMED: | 23264903 |
| Notes: | --- - Review - "Source: Wos" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work